Prospective, uncontrolled, open-label study evaluating the safety and clinical performance of 3C Patch® in chronic wounds with different etiologies that had failed to heal using conventional, standard treatment approaches.
*3C Patch is formerly known as Leucopatch
3C Patch® was prepared from blood donated by patients at the point of care and applied to their wounds once a week for six weeks, or until the wounds were completely healed.
15 patients included
(16 wounds in total)
Adult patients, with chronic cutaneous ulcers on the lower extremities, chronic diabetic foot ulcers or amputation wounds. DFU grade 1 or 2 according to the Wagner scale
Most of the wounds included in the study had been present for 2 years or more
Significantly Increased Granulation
The proportion of granulation tissue present in the wounds increased significantly during the study from a mean of 32% at baseline to 72% at week six.
Significant Decrease in Wound Area
By six weeks wound area decreased by a mean of 65%.
Key Safety Data
Only two adverse events recorded, none of which was serious. Neither was considered to be related to the 3C Patch® treatment. No safety issues were identified.